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The authors have developed a simple, nested polymerase chain reaction 
(PCR) assay for amplification of an outer surface protein A (OspA) 
gene fragment of Borrelia burgdorferi using rapid temperature cycling 
and ethidium bromide detection on agarose gels, and applied it to the 
diagnosis of Lyme disease in humans. With denaturing and annealing 
temperature spikes instead of holds, cycle times were less than 20 min­
utes for a 30-cycle amplification. Using this rapid cycle PCR technique, 
as few as 5 spirochetes per mL of phosphate buffered saline were de­
tected. In addition, B  burgdorferi DNA was detected from spirochetes 
that had been spiked into one of several types of human body fluids 
including serum, synovial fluid, and cerebrospinal fluid (CSF). A num­
ber of clinical samples, which had been tested for Lyme immunoglobu­
lin M  (Ig M ) and immunoglobulin G (IgG) antibody were also examined.
In 29 serologic positive samples (14 IgG and IgM  positive, 9 IgM alone 
and 6 IgG alone), B burgdorferi DNA was not detected. In contrast, 
nine serum samples and one synovial fluid from patients with definite 
clinical features of Lyme disease were found to be negative by EIA and 
Western blot analysis for IgG and IgM  antibody, but contained B bur­
gdorferi DNA, as detected by PCR. Polymerase chain reaction analysis 
of serum and synovial fluid may be of significant diagnostic value in 
Lyme disease, especially in the absence of a serologic response in early, 
partially treated and seronegative chronic disease. This is the first study 
to report an association between PCR positivity and the absence of a 
serologic response to Lyme borreliosis. (Key words: Polymerase chain 
reaction; Borrelia burgdorferi; Serum; Rapid cycle amplification) Am J 
Clin Pathol 1996;105:647-654.
■ Lyme disease is caused by the tick-borne spirochete Bor­
; relia burgdorferi.' There is great difficulty associated 
with making a definitive diagnosis of this disease for sev- 
= eral reasons. First, manifestations of Lyme disease are 
varied and rarely clear cut. Generally, the presence of the 
: skin rash, erythema migrans (EM), is the best indicator 
of infection. However, this type of rash is lacking in 20% 
to 40% of the cases.2 Musculoskeletal, neurologic, and 
cardiovascular involvement occurs in Lyme disease, but 
may be present in a variety of combinations and gener­
ally appears later in the course of the disease.2 Therefore, 
Lyme disease can be very misleading and difficult to di-
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agnose in the early stages, particularly if EM is not pres­
ent. A second major problem is associated with the im­
mune response to B burgdorferi. Many affected 
individuals do not mount an immune response until af­
ter the organism has reached the joints, central nervous 
system, or the heart. Even when an immune response is 
present, it may be variable and difficult to interpret.3 The 
third problem lies in the inability of the available sero­
logic tests to eliminate cross reactivity with other spiro­
chetes and to be sensitive enough to detect low levels of 
antibody.4,5
Because of the problems associated with detecting and 
interpreting an immune response, the use o f the poly­
merase chain reaction (PCR) to detect the DNA from B 
burgdorferi seems promising. We have developed a 
nested PCR assay using rapid cycle DNA amplification 
techniques to detect the outer surface protein A (OspA) 
gene, which is located on a 49-kb plasmid contained 
within the spirochete.6 The OspA gene has been shown 
to be highly specific for B burgdorferi.1* The nested PCR 
assay we used makes use of a rapid air thermocycler to 
amplify the products.9'10 Nocton and colleagues11 have 
performed PCR for OspA sequences on the joint fluid of
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l .  OLIGONUCLEOTIDE PRIMER SEQUENCES FOR BORRELIA BURGDORFERI OspA GENE
Primer Name Position Base No. Sequence 5’-3'
Outer set Bb-1 152-177 TGA A A A A AT ATTT ATTGGGA AT AGGT
Bb-2 340-316 TAAGCTCAAGCTTGTCTACTGTTGC
Inner set Bb-3 202-224 AAGCAAAATGTT AGCAGCCTTGA
Bb-4 295-268 CTTTGTTTTTTTCTTTGCTTACAAGAAC |:;j
patients with chronic Lyme arthritis and have found B 
burgdorferi in 85% of the patients. We hypothesized that 
it might be possible to make an accurate diagnosis of 
early or chronic Lyme disease by examining serum or 
plasma samples. Our preliminary data, on a limited 
number of cases, suggest that PCR can be positive in 
such samples, especially if they are obtained before a se­
rologic response to B burgdorferi is present To our 
knowledge, this is the first study in which a negative cor­




Gene sequences from 20 OspA isolates were identified 
in GENBANK and 2 sets of primers were chosen with 
91 % homology to all sequences (Table 1). Primer BB-1 is 
paired with primer BB-2 to form an outer primer set that 
produces a PCR product that is 189 base pairs (bp) in 
length. The nesting primer set is made up of primers BB-
3 and BB-4 and amplifies a 93 bp product. Primers were 
synthesized by phosphoramidite, solid phase chemistry 
(Pharmacia LKB-Gene Assembler Plus; Pharmacia Bio­
tech, Uppsala, Sweden).
PCR Reaction Mixture
One imL of sample DNA was mixed in a U-bottom mi­
crotiter dilution tray with nine mLs of a reaction mixture 
containing 0.50 mM of each primer, 200 mM of each 
deoxynucleotide triphosphate (Pharmacia Biotech, Up­
psala, Sweden), 50 mM tris-hydrochloride, 3 mM mag­
nesium chloride, 2.5 mg/mL of BSA, 0.5% Ficoll, 1 mM 
tartrazine, and 0.4 Units of Taq polymerase (Amplitaq, 
Perkin-Elmer Cetus, Norwalk, CT) in sterile distilled 
H20 . Reagents were from Sigma (St. Louis, MO) unless 
otherwise specified.
Product Amplification
The above reaction mixture was drawn from the 
microtiter tray into a 10 nL  glass capillary tube (0.56 
mm internal diameter). After the ends of the capillary
were sealed the tube was placed in a Model 1605 rapid ■ 
air thermocycler (Idaho Technology, Idaho Falls, ' 
ID), where it was temperature-cycled for 40 cycles. 
By using sharp temperature spikes instead of holds at 1 
denaturation and annealing, cycle times for DNA 
amplification can be reduced from 4 to 6 minutes per 
cycle down to 30 seconds.12 Nesting was performed 
by aspirating 1 nL of amplified product from the tip 
of the capillary with the use of a clean pipet tip at­
tached to a dedicated pipettor. This 1 pL  from the first 
amplification was mixed in a sterile microtiter dilu­
tion tray with 9 fih of a new amplification mixture 
containing the nested primers. For nesting, the exten­
sion time was lowered to 1 second and the samples 
were run for 30 cycles. Amplified product was re­
solved by running 10 juL on 1.5% agarose gels 
(SeaKem agarose, FMC Corporation, Rockland, 
ME). Gels were run at 80 V for 30 to 45 minutes, in a 
solution oftrizma base, boric acid, EDTA (TBE) with 
0.5 mg/mL ethidium bromide. DNA was visualized 
on a UV transilluminator at 300 nm and compared to 
molecular weight markers (50-1000 bp), (Bio Ven­
tures, Murfreesboro, TN). The total time for ampli­
fication, nesting, and gel electrophoresis was approx­
imately 2 hours.
Because of the problems associated with contamina­
tion and false positivity, we incorporated strict guidelines 
for maintaining a sterile working environment and uni­
directional work flow between three distinctly separate 
work stations. Sterile disposable equipment and dedi­
cated pipettors were used for every reaction, and reaction 
mixtures were made up by adding the sample DNA as 
the last component.
Samples were run in duplicate along with positive con­
trols made from whole blood inoculated with approxi­
mately 400 spirochetes per mL and negative controls 
from a known negative donor.
PCR Protocol
Our primer sets were optimized13> 14 by running a series 
of reactions using 1, 2, 3, 4, and 5 mM magnesium chlo­
ride at annealing temperatures varying from 40 °C. to 
60 °C. The final optimized protocol for the primary am­
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plification was as follows: denaturation at 94 °C for less 
than 1 second, annealing at 47 °C for less than second, 
and elongation of 72 °C for 5 seconds. For the secondary 
or nested amplification, all of the cycling parameters 
were the same except for the elongation time that was 
lowered to 1 second.
Restriction D igest
T o ensure that the final DNA product contained the 
correct sequence, we used the restriction enzyme Bst71 1 
(promega, Madison, WI), which recognizes a 5 base se­
quence within the inner primer product. One unit of the 
restriction enzyme was allowed to locate the template se­
quence of the 93 bp product and cut it during a 16-hour 
incubation at 37 °C. This cut produces fragments at 27 
and 66 bp.
Specificity o f our primers was checked by attempting 
to amplify spirochete DNA from buccal swabs obtained 
from  five normal donors. DNA isolation and PCR for 
these samples was done simultaneously with the positive 
and negative controls described above. Genomic DNA 
in each sample was verified by amplifying the D1S80 lo­
cus.
D N A  Isolation Techniques
Four different methods of DNA isolation were evalu­
ated. The first method was to simply boil the samples. In 
the second method, samples were spun at 16,000 X g for 
15 m inutes and the pellet was digested with proteinase K 
(Sigma) in sodium dodecyl sulfate (SDS) digestion buffer 
(0 .2M  trizma base, 0.05M EDTA and 1% SDS, pH 8.0). 
T his was followed by a standard phenol/chloroform ex­
traction and ethanol precipitation. DNA was diluted in 
J X  Tris EDTA (TE) buffer to an A260 reading of 1.0 and 
boiled  for 5 minutes. In the third method, samples were 
again spun at 16,000 X g for 15 minutes and the pellet 
w as digested with 5 /iL of proteinase K mixed with 45 mL 
o f  a  Tween 20 digestion buffer (0.02M trizma base, 
0 .0 5 M  EDTA and 1% Tween 20, pH 8.5). Following a 1- 
h ou r incubation at 55 °C, the samples were boiled for 5 
m inutes. The fourth method made use of a solid phase 
D N A  isolation kit (IsoQuick; Microprobe, Garden 
G rove, CA), which uses guanidine thiocyanate and 
nuclease adsorption with an extraction matrix. Twenty 
Mg o f  glycogen were added to each sample as a DNA car­
rier. Purified DNA from this method was resuspended in 
50 /iL  o f  RNase free water. One nL of DNA from all 
sam ples was used to perform PCR.
B a c te r ia  and Sam ple Spiking
Spirochetes of the N40 isolate, passage 5, were cul­
tu red  in BSK-II (Sigma) media at 30 °C and counted us­
ing dark field microscopy. Spirochetes were diluted in 
PBS from 400 spirochetes per mL down to 5 spirochetes 
per mL. Diluted spirochetes were then added to either 
PBS alone, or a variety of human body fluids. The pur­
pose for using spirochetes diluted in PBS was to deter­
mine the optimal sensitivity limits for the assay without 
the possible interference of any non-i? burgdorferi debris 
to affect the PCR. Spirochetes were also spiked into the 
human body fluids for the purpose of determining the 
sensitivity limits for each specific sample type. For sam­
ple spiking experiments, we chose to use whole blood, 
plasma, serum, synovial fluid, CSF, and urine from nor­
mal donors. Spirochetes were added to each human sam­
ple type in varying concentrations and incubated over­
night at 30 °C. so as to allow the spirochetes to bind to 
any cellular structures. The spirochetes do not undergo 
significant cell division under these conditions. DNA 
was then extracted using proteinase K in Tween 20 di­
gestion buffer. Spirochetes diluted in PBS did not un­
dergo overnight incubation and were processed shortly 
after inoculation.
Clinical Samples
Specimens used in this study were obtained from a va­
riety of suspected Lyme disease patients. A majority of 
the samples were sent as serum to our reference labora­
tory for general serological testing by enzyme immuno­
assay and/or Western blot (MarDx Diagnostics, Carls­
bad, CA). It was assumed that samples that were 
considered Lyme serologically positive by either EIA 
and/or Western blot testing were from patients who cur­
rently exhibited or were recovering from Lyme type dis­
ease (ie, erythema migrans, chronic arthritis, or neuro­
logic impairment). Generally, those patients who 
presented with positive IgG results alone would be con­
sidered as having past exposure to B burgdorferi. 
Whereas, those patients who exhibited positive IgM or 
IgG and IgM would be considered to have more recent 
or acute infection and be in the earlier stages of disease. 
We assumed that those samples that tested negative by 
serology and PCR were obtained from patients who were 
affected by some type of Lyme-associated illness based 
on the fact that they were sent to us specifically for Lyme 
testing. Even patients whose samples were sent to us 
merely to rule out Lyme disease must be considered po­
tential candidates for having the disease. Therefore, ev­
ery patient included in this study most likely had symp­
toms that were at least suggestive of Lyme disease. 
Unfortunately, we do not know whether the symptoms 
were suggestive of early or late disease. Because ours is a 
reference laboratory receiving specimens from other 
medical centers or regional laboratories, clinical data on
Vol. 105-No. 5
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the patients, including symptoms, timing of the sample, 
and physical findings, are almost never available, even 
after repeated requests. However, we were able to get 
clinical data on all 10 samples with positive PCR results 
after an exhaustive effort.
A small panel of 10 plasma and serum samples, sent 
to us by Boston Biomedica (West Bridgewater, MA) was 
also included in this study. This panel was tested by nine 
laboratories using four different serologic methodolo­
gies. Nine of the samples were selected to demonstrate 
IgG and/or IgM reactivity.
It was necessary to verify that our methods of DNA 
isolation could be used to isolate minimal quantities of 
genomic DNA so that we could feel confident in report­
ing negative results for Lyme PCR. For this, we used 10 
sera obtained from 10 different blood donors. Because 
serum lacks a significant cellular population, we added 
approximately 25 cultured lymphocytes to each sample, 
before DNA extraction. After the DNA was isolated each 
sample was tested for the presence of human genomic 
DNA by using oligonucleotide primers specific for the 
beta-globin gene. After testing each sample for the pres­
ence of human genomic DNA, we tested each sample 
using primers for B burgdorferi.
RESULTS
Confirmation of Primer Specificity
In Figure 1, we amplified and detected the B burgdorf­
eri DNA using both the inner and outer primers without 
nesting (Lanes 4 and 5). By using a nested PCR assay, 
the bands for our inner nested product (Lane 3) become 
much more intense and defined in comparison to the 
nonnested products of Lanes 4 and 5. We identified our 
final nested primer product by using restriction enzyme 
Bst71 I. This restriction enzyme was able to recognize a 
specific sequence within the nested primer product in 
Lane 3 and make a cut at 8 and 12 bp downstream from 
the recognition site. The restriction digest worked to pro­
duce two new bands at 66 and 27 bp (Lane 2).
Comparison of B o r r e l ia  b u r g d o r f e r i  DNA Isolation 
M ethods
Spirochetes were diluted in PBS from 200 spirochetes 
per mL down to 1 spirochete per mL and DNA was ex­
tracted by each of the previously described methods. 
Boiling the samples followed by PCR amplification of 1 
/jlL  of sample failed to demonstrate spirochete DNA at 
any of these levels. Centrifugation, followed by phenol/ 
chloroform extraction of the pellet and ethanol precipi­
tation, allowed us to detect B burgdorferi DNA at the
1 2 3 4 5 6
—  2 0 0  bp  
—  1 0 0  bp  
—  50  bp
Fig. 1. Product identification using restriction enzyme Bst711. Agarose 
gel electrophoresis of rapid cycle PCR-amplified products from N4G 
isolate of Borrelia burgdorferi. Lane 1 (Left lane): negative control that 
was isolated from uninfected Balb/c mouse heart. Lane 2: inner nested 
product after digestion with restriction enzyme Bst71 I. Lane 3: inner 
nested primer product, at 93 bp, from positive sample that was isolated 
from infected Balb/c mouse heart. Lane 4: 93 bp product amplified 
from infected Balb/c mouse heart using the inner primer set only with­
out nesting. Lane 5: Outer nonnested primer product, at 189 bp, also 
isolated from infected Balb/c mouse heart. Lane 6: molecular weight 
marker (BioVentures).
level of 200 spirochetes per mL in PBS. In contrast, by 
using the proteinase K in Tween 20 digestion buffer and } 
the Isoquick methods, we were able to detect B burgdorf- j 
eri DNA down to 5 spirochetes per mL of PBS. Extrac- j 
tion and PCR analyses were performed 3 to 4 times in \ 
these experiments. Because the Tween 20 and IsoQuick i 
methods yielded the same results, we chose to continue j 
our sensitivity experiments using the Tween 20 method ; 
of DNA isolation. Figure 2 illustrates the effectiveness ■ 
of the proteinase K in Tween 20 method for isolating B  
burgdorferi DNA at different concentrations of spiro- ' 
chetes. The positive control is shown in Lane 2 and pos­
itive bands are found at 93 bp. From the figure, we can 
see that DNA was positively identified in the 5, 10, 25, ; 
and 50 spirochete samples (Lanes 5 through 8). Con­
versely, there are no positive bands in the negative con­
trol (Lane 3) and in the one spirochete per mL samples 
(Lane 4). Lower bands shown at approximately 60 bp are 
probably the result of the formation of primer dimers.
Sample Inoculation Experiments
After determining sensitivity in PBS, we inoculated a 
variety of human body fluids with B burgdorferi. DNA  
was isolated by the Tween 20 method and subsequently 
amplified. Samples, which yielded the greatest sensitiv­
ity, were plasma, synovial fluid, and CSF. In these sam­
ple types, we could detect as few as 10 spirochetes per 
mL of sample. We detected down to 20 spirochetes per
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1 2 3 4 5 6 7 8
Fig. 2 . Sensitivity of spirochete DNA detection using rapid cycle PCR 
and visualized by agarose gel electrophoresis and ethidium bromide 
staining. DNA was isolated by proteinase K in Tween 20 digestion 
buffer from  spirochetes spiked directly into PBS. Lane 1 (Left lane): 
B iom arker low molecular weight marker (BioVentures). Lane 2: posi­
tive contro l isolated from infected Balb/c mouse heart. Lane 3: negative 
contro l isolated from uninfected Balb/c mouse heart. Lane 4: is a sam­
ple w hich contained approximately 1 spirochete per mL of PBS. No 
am plifiable spirochetal DNA was detected in this sample. Lane 5: Bor­
relia burgdorferi DNA amplified from a 5 spirochete per mL sample. 
Lane 6: B  burgdorferi DNA amplified from a 10 spirochete per mL 
sam ple. L ane 7: B burgdorferi DNA amplified from a 25 spirochete per 
m L  sam ple. Lane 8: B burgdorferi DNA amplified from a 50 spirochete 
per m L  sample.
m L in serum samples, 50 spirochetes per mL in urine, 
and 100 spirochetes per mL in whole blood. Extraction 
and PCR analyses were performed 2 to 3 times for each 
body fluid.
C lin ical Samples
Table 2 compares results of serology and PCR data 
from  67 samples. All samples had DNA isolated by both 
the IsoQuick and proteinase K in Tween 20 methods of 
extraction. Fourteen of the samples were identified as 
positive for both IgG and IgM. However, none had de­
tectable B  burgdorferi DNA by PCR. Nine of the samples 
were positive for IgM and negative or equivocal for IgG. 
These nine samples were negative for B burgdorferi 
D N A . Six samples, which were positive for IgG antibod­
ies only, were also negative for B burgdorferi DNA. Of 
the remaining 28 samples with negative PCR results, all 
had either negative or equivocal antibody results, with 
the exception of seven that were initially sent to our lab­
oratory for PCR testing and had insufficient sample vol­
um es for serologic testing.
N in e o f  the serum samples and one synovial fluid sam­
ple had B  burgdorferi DNA present by PCR. None of 
these samples contained antibody to B burgdorferi (Ta­
ble 3).
Positive samples 1 and 2 were obtained from a 40- 
year-old man described as an avid hiker who lived in the 
New England area until 1988 when he moved to the 
West Coast. In 1989, the patient was diagnosed with 
Bell’s palsy and has had three episodes since that time 
without etiology. The patient has had no rash or derma­
titis and no detectable neurologic or cardiac involve­
ment.
Positive samples 3 and 4 were from a 47-year-old man 
who had a tick bite followed by a characteristic EM cir­
cular rash in the right groin, first noticed in May of 1994. 
The rash dissipated and reappeared in August of 1994 
when the first serum sample was sent for PCR analysis. 
At that time, no antibiotic therapy had been adminis­
tered. In September 1994, the rash was suspected to be 
more likely due to Tinea corporis, and the patient was 
treated with antifungal therapy. It was after this last epi­
sode that the second serum sample was sent for Lyme 
PCR testing.
Positive samples 5 and 6 were from a 40-year-old man 
who presented with EM in the ankle region 18 months 
before PCR analysis. No antibiotic treatment was given 
before PCR testing.
Positive sample 7 was a grossly hemolyzed serum sam­
ple. This patient was a 66-year-old woman known to 
have had rashes consistent with Lyme disease, including 
a specific EM type rash on the left thigh approximately 4 
years before PCR analysis. This patient also complained 
of neck and hip arthralgias.
Positive sample 8 was from a 51-year-old woman with 
chronic arthritis of the hips and knees without a history 
of a Lyme type rash.
Positive sample 9 was from a 10-year-old boy who pre­
sented with an insect bite on the scalp and an associated 
lesion approximately 3 months before PCR analysis. The 
patient subsequently was diagnosed with Bell’s palsy, 
headaches, and alterations in mentation. Antibiotic ther­
apy was not administered before PCR testing.
Positive sample 10 was from a 31-year-old woman 
with frequent exposure to numerous farm animals and 
numerous insect bites. She did not exhibit any type of 
rash but did experience memory changes, headaches, 
and arthralgias. This patient had begun antibiotic ther­
apy with doxycycline and ceftriaxone 2 weeks before 
PCR analysis.
We were unable to detect any B burgdorferi DNA from 
any of the 10 samples included in the Boston Biomedica 
panel including 9 serology positive and 1 serology-nega­
tive serum.
Testing 10 blood donor sera (spiked with a minimal 
number of cultured lymphocytes) for the presence of 
the B-globin gene revealed human genomic DNA in
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13 Serum Positive Positive Absent
1 Plasma Positive Positive Absent
14
7 Serum Negative Positive Absent
1 Serum Equivocal Positive Absent
1
Q
Plasma Negative Positive Absent
y
2 Serum Positive Negative Absent
3 Plasma Positive Negative Absent
1
f.
CSF Positive Negative Absent
0
6 Serum Negative Negative Absent
2 Blood Negative Negative Absent
1 Synovial Negative Negative Absent
2 Urine Negative Negative Absent
8 CSF Negative Negative Absent
1 Plasma Equivocal Negative Absent
1 Serum Equivocal Equivocal Absent
2 Serum QNS QNS Absent
4 CSF QNS QNS Absent
1 Blood NA NA Absent
28
9 Serum Negative Negative Present
1 Synovial Negative Negative Present
10
QNS = quantity not sufficient for testing; Ig = immunoglobulin; NA = serology results not available; Absent = no Borrelia burgdorferi 
DNA detected; Present = Borrelia burgdorferi DNA detected; CSF = cerebrospinal fluid.
all 10 samples. Thus, the negative results for these 
samples were not the result of failed DNA extraction 
or amplification. Further testing o f these samples using 
the primers specific for B burgdorferi showed that B
burgdorferi was absent from all of these 10 blood bank 
samples.
Overall, we performed serology and PCR testing on 67 
samples from patients that had suspected Lyme disease.
TABLE 3. SEROLOGY RESULTS AND CLINICAL FEATURES OF BORRELIA BURGDORFERI POLYMERASE CHAIN
REACTION (PCR) POSITIVE PATIENTS
Sample ARUP ARUP ARUP PCR
Sample Type IgG EIA IgM EIA Western Blot Result Symptoms
1 Serum 0.21 0.07 Negative Present Bell’s palsy
2 Serum 0.06 0.07 Negative Present Bell’s palsy
3 Serum 0.22 0.16 Negative Present EM following tick bite
4 Serum 0.37 0.14 Negative Present EM following tick bite
5 Synovial 0.00 0.00 Negative Present EM, 2-3 cm pigmented lesions on leg 
Rash in ankle region, lesions with clearing
6 Serum 0.36 0.39 Negative Present EM, 2-3 cm pigmented lesions on leg 
Rash in ankle region, lesions with clearing
7 Serum 0.30 0.19 Negative Present EM on left thigh 
Neck and hip arthralgias
8 Serum 0.10 0.21 Negative Present Chronic arthritis in hips and knees
9 Serum 0.65 0.90 Negative Present Insect bite with lesions on scalp
Bell’s palsy, headaches, alterations in mentation
10 Serum 0.22 0.77 Negative Present High exposure to farm animals with subsequent tick bites 
Memory changes, headaches, and arthralgia
EM - erythema migrans; EIA = enzyme immunoassay; ARUP * Associated Regional and University Pathologists; Ig = immunoglobulin. 
Enzyme immunoassay results are negative for values below 0.91. Samples 1 and 2 are from the same patient, before treatment, with a 
J -month time difference. Samples 3 and 4 are from the same patient, before treatment, with a 1 -month time difference. Samples 5 and 6 are 
also from the same patient, before treatment, with a 1-month time difference.
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Among these 67 samples, we detected nine positive 
(13%) samples by PCR from seven patients. These nine 
samples were repeatedly positive. Thirty-four of the total 
67 samples were submitted specifically for Lyme PCR 
testing from 29 patients. The remaining 33 samples were 
sent for Lyme serology testing and selected at random 
for PCR analysis. Of the 34 samples submitted for PCR 
testing, 9 sera and 1 synovial fluid sample were positive 
by PCR, but negative by serology. These nine samples 
came from seven patients exhibiting characteristic Lyme 
features (ie, erythema migrans, arthritis, and neurologic 
involvement). Three patients had positive PCR results 
for B burgdorferi from more than one sample. Seven 
(24%) of the 29 patients suspected of Lyme disease, who 
had samples sent specifically for PCR analysis were 
found to have B burgdorferi DNA present. In contrast, 
30 of the total 67 samples were positive or equivocal for 
either IgM, IgG, or both, and yet none of these 30 sam­
ples were found to contain B burgdorferi DNA. We be­
lieve that this lends evidence to the fact that the presence 
of antibody has some bearing on the outcome of the 
PCR, most likely because the antibody has the ability to 
eliminate the already low numbers of spirochetes present 
in the serum. This does not suggest that the spirochete 
may not still be present in higher numbers in other tis­
sues or fluids such as joint fluid, the heart or skin.
DISCUSSION
The objective of this study was to determine if a 
nested, rapid cycle amplification technique could be 
used to detect B burgdorferi DNA in clinical samples, 
including serum, and determine the relationship be­
tween the serologic status of the patient and PCR positi- 
vity. Using primers to the OspA gene we were able to 
detect B burgdorferi DNA by amplifying an outer primer 
product at 189 bp and finally an inner nested product at 
93 bp. Positive identification of B burgdorferi DNA was 
performed using DNA isolated from infected Balb/c 
mice and whole blood samples spiked with spirochetes. 
Restriction enzyme Bst71 I digestion confirmed the 
identity o f the OspA gene. Lebech and Hansen7 and Lei- 
bling and colleagues8 have also indicated that the OspA 
gene is specific for B burgdorferi.
We were able to determine the in vitro sensitivity of 
our test by spiking various numbers of spirochetes into 
PBS and isolating the DNA using the four different 
methods described above. Adding the spirochetes to PBS 
greatly reduced the possibility of any inhibitors in the 
PCR reaction. Figure 2 illustrates that we were able to 
detect as few as five spirochetes using the proteinase K in 
Tween 20 DNA isolation method. Similar results were 
also found for the IsoQuick method of extraction. One
advantage to using the IsoQuick method is that the final 
sample is generally cleaner with a pure DNA product. 
The advantage to using the proteinase K in Tween 20 
method is that sample isolation takes place in only one 
microcentrifuge tube, which minimizes sample loss. 
These data suggest that either method of DNA isolation 
gives sensitive, comparable results.
Through inoculating a variety of human body fluids 
with B burgdorferi spirochetes, we were able to establish 
which sample types had inhibitory effects on the PCR 
reaction. By adding spirochetes in varying concentra­
tions to each of the different sample types and allowing 
them to incubate, we hoped to simulate what might be 
seen in vivo. Spirochetes could be detected in each of the 
sample types with a sensitivity of down to 10 spirochetes 
in the plasma, synovial fluid, and CSF. We could only 
detect down to 100 spirochetes in whole blood samples. 
Leidtke and colleagues15 have indicated that the presence 
of hemoglobin may have inhibitory effects on PCR in 
whole blood samples.
Our methods of DNA isolation were capable of ex­
tracting DNA from 10 of 10 blood bank donor serum 
samples spiked with a low number (25 cells) of lympho­
cytes. Further testing of these samples for the presence of 
B burgdorferi organisms showed that all samples were 
negative for this organism. This observation illustrates 
that the DNA isolation techniques that we have de­
scribed are capable of isolating available DNA in 100% 
of the samples, Therefore, samples that do not have 
bands present after gel electrophoresis are in fact actual 
negative samples and are not due to failure of the DNA 
isolation technique. One must keep in mind that a nega­
tive result can be because of concentrations of spiro­
chetes below the limit of detection, or lack of any spiro­
chetes in the patient samples.
Leibling and colleagues8 have shown that it is possible 
to detect the OspA gene of B burgdorferi in serum and 
other samples using PCR. In results similar to ours, these 
authors could detect as few as 10 spirochetes per mL of 
fluid using a phenol/chloroform extraction method. We 
believe that one of the most critical points of our study is 
that, using the DNA isolation methods and PCR tech­
niques described previously, B burgdorferi DNA was re­
peatedly detected in serum samples (9 of 22 samples, or 
41% of serum samples sent specifically for Lyme PCR). 
It is also important that all of the samples which con­
tained B burgdorferi DNA, as detected by PCR, were 
negative for antibody by EIA and Western blot. It is a 
known fact that the level of spirochetes (for most pa­
tients) contained in blood are low and it appears, at least 
in the cases we have presented in this study, that once an 
immune response is mounted spirochete DNA appears
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to be eliminated from the serum. Although the sensitiv­
ity of the test may not be high, finding B burgdorferi 
DNA in serum almost certainly establishes the diagnosis 
of borreliosis in the patients. Moreover, we think this 
finding may be important in the dissemination and, 
therefore, the pathogenesis of the disease. We realize that 
the general sensitivity of PCR testing may never achieve 
an acceptable level to be useful as a routine screening test 
for infection. However, it may be extremely useful in the 
unusual seronegative patient with disease compatible 
with that caused by B burgdorferi.
In conclusion, we believe that this type of testing may 
be of significant value in the detection of early Lyme dis­
ease or disease in which an adequate serologic response 
has not developed. We strongly suggest performing PCR 
on duplicate samples as low copy numbers are likely 
present, especially in serum. We also suggest testing skin 
biopsies from typical lesions, synovial fluid, and CSF 
along with serum of suspected patients. A positive test 
has great significance in establishing the etiology of a 
Lyme-like illness, whereas a negative PCR result cer­
tainly does not exclude B burgdorferi infection.
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